Oncosil Medical Eyes June Readout That Could Expand Pancreatic Cancer Approval
OncoSil confirms TRIPP-FFX trial results on track before end of June 2026
OncoSil Medical (ASX: OSL), a medical device company focused on localised treatment for unresectable locally advanced pancreatic cancer (LAPC), has confirmed it remains on track to announce initial TRIPP-FFX trial results to the market before 30 June 2026. With 88 patients enrolled across 15 sites in Europe and Australia, the readout represents a near-term catalyst for investors tracking the clinical-stage company.
When big ASX news breaks, our subscribers know first
What the TRIPP-FFX trial is testing and why it matters
TRIPP-FFX stands for TaRgeted Intratumoural Placement of Phosphorous-32 + FOLFIRINOX. The trial evaluates the OncoSil™ device, which delivers Phosphorous-32 (32P) microparticles directly into pancreatic tumours, enabling a greater radiation dose to be applied to the tumour while sparing surrounding organs compared to external beam radiotherapy.
The trial is an open-label, multi-centre, randomised investigation comparing the OncoSil™ device used in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX alone in patients with unresectable LAPC. FOLFIRINOX is a combination chemotherapy regimen already used as a standard-of-care option for this patient population, and its inclusion in the trial is significant: a successful outcome could allow FOLFIRINOX to be formally listed alongside gemcitabine-based chemotherapy as an approved treatment combination with the OncoSil™ device, broadening the eligible patient base.
Trial endpoints at a glance:
- Primary: Safety and Tolerability; Local Disease Control Rate (LDCR) at 16 weeks
- Secondary: Local Progression-Free Survival (LPFS), Progression-Free Survival (PFS), Overall Survival (OS), tumour response rate, surgical resection rate, quality of life, and pain scores
The scale of the addressable patient population reinforces the commercial relevance of a positive readout. Pancreatic cancer is the 12th most common cancer in men and 11th most common in women globally, with approximately 500,000 new cases diagnosed each year. Given the disease is typically identified at a late stage, treatment options that can improve local disease control carry significant clinical weight.
Understanding the regulatory design and what results will and won’t show
TRIPP-FFX was designed specifically to meet EU MDR clinical evidence requirements for an existing CE Mark registration as a Class III Active Implantable Medical Device. Understanding this design choice is important for interpreting the upcoming results accurately.
The trial was not prospectively powered to demonstrate statistically significant differences between treatment arms, and p-values will not be reported when results are released. This is intentional, not a limitation. Running a statistically powered superiority trial would have required substantially more patients and a considerably longer timeframe to complete.
Key regulatory design context
The TRIPP-FFX study was designed to evaluate safety and generate supportive evidence of clinical benefit, consistent with EU MDR requirements for active implantable medical devices.
Under the EU MDR framework, clinical evidence for active implantable medical devices is assessed through an overall benefit-risk evaluation conducted by an EU Notified Body, rather than through a statistical superiority test. The trial design reflects the fact that OncoSil™ already holds CE Mark approval in Europe, received in April 2020. The upcoming submission is therefore an extension of an existing approval, not a first-in-class regulatory filing.
Investors should expect the initial results announcement to focus on safety, tolerability, and LDCR data at 16 weeks, presented within this benefit-risk framework.
The next major ASX story will hit our subscribers first
The regulatory submission pathway and what comes next
Subject to the outcomes of the trial, OncoSil Medical expects to file a regulatory submission in late CY2026. If successful, the submission would extend the company’s current EU MDR approval for the OncoSil™ device by broadening the chemotherapy regimens within the indications for use to allow FOLFIRINOX as an additional chemotherapy option for patients with unresectable LAPC, alongside its current approved use with gemcitabine-based chemotherapy.
The trial itself will continue beyond the initial results announcement, with long-term overall survival data collection remaining ongoing.
Upcoming milestones:
- Initial TRIPP-FFX results announced — before 30 June 2026
- Regulatory submission filed — target late CY2026
- Long-term overall survival data collection — ongoing
OncoSil™ currently holds approval in 30+ countries, including across the European Union, United Kingdom, Australia, Türkiye, and Israel. Commercial treatments using the device have already been undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel, and the UK, providing an established commercial foundation ahead of any potential indication extension.
Don’t Miss the Next Healthcare Catalyst
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who never miss a market-moving announcement. Click the “Free Alerts” button at StockWire X to stay ahead the moment results land.